e-ISSN: 0976-822X, p-ISSN:2961-6042

Available online on http://www.ijcpr.com/

International Journal of Current Pharmaceutical Review and Research 2026; 18(2); 2128-2132

Original Research Article

Efficacy of Probiotic Supplementation in Children for Prevention and Treatment of Common Pediatric Illnesses

Navin Kumar[1], Anchala Kumari[2], Ashok Kumar[3]

[1]Senior Resident, Department of Paediatrics, Darbhanga Medical College & Hospital, Darbhanga, Bihar, India

[2]Senior Resident, Department of Paediatrics, Darbhanga Medical College & Hospital, Darbhanga, Bihar, India

[3]HOD, Department of Paediatrics, Darbhanga Medical College & Hospital, Darbhanga, Bihar, India

Received: 24-12-2025 / Revised: 23-01-2026 / Accepted: 25-02-2026

Corresponding Author: Anchala Kumari

Conflict of interest: Nil

Abstract:

Background: Live bacteria known as probiotics are beneficial to health when taken in sufficient quantities. They are being used more and more in pediatric populations to treat and prevent common ailments like respiratory infections, gastrointestinal disorders, and diarrhea.

Objective: To evaluate the efficacy of probiotic supplementation in reducing the frequency of common pediatric illnesses among children.

Methods: Eighty children between the ages of one and twelve who were taking probiotic supplements participated in an observational study. Medical records and caregiver reports were used to gather information on clinical results, probiotic duration, and demographics. Descriptive statistics and chi-square tests were used in the statistical analysis to see whether the length of probiotic supplementation and the results of disease were related.

Results: Of the 80 children, 26.2% had frequent illness, 31.3% had no change, and 42.5% had fewer occurrences of illness. There was no statistically significant correlation between the length of probiotic administration and clinical outcomes ($p = 0.9165$).

Conclusion: Many children who took probiotic supplements reported fewer instances of illness, while there was no statistically significant correlation between the length of supplementation and illness. To verify the efficacy of probiotics in pediatric healthcare, more controlled research is needed.

Keywords: Probiotics, Pediatric illness, Observational study, Child health, Gastrointestinal health.

DOI: 10.25258/ijcpr.18.2.351

Introduction

Childhood ailments, including gastrointestinal infections, respiratory tract infections, and severe diarrhea, continue to pose considerable global health challenges, significantly impacting juvenile morbidity and escalating healthcare consumption. These problems adversely impact the physical health of children and impose a significant strain on families and healthcare systems. In recent years, probiotics have garnered interest as a potential preventive and therapeutic intervention in pediatric healthcare [1]. Probiotics are live microorganisms, mostly bacteria and yeasts, that provide health advantages when consumed in sufficient quantities. Prevalent probiotic strains encompass Lactobacillus, Bifidobacterium, and Saccharomyces boulardii, each contributing significantly to the maintenance of gut microbiota equilibrium, the enhancement of intestinal barrier integrity, and the modulation of immunological responses [2].

Numerous studies have shown that probiotics help diminish the frequency and duration of prevalent pediatric ailments. Probiotics have demonstrated efficacy in controlling infectious diarrhea, avoiding antibiotic-associated diarrhea, and reducing the incidence of respiratory tract infections in children [3]. Their advantageous effects are ascribed to processes including the suppression of harmful organisms, the synthesis of antimicrobial compounds, and the promotion of both innate and adaptive immunity [4]. Moreover, probiotics may enhance gut health and general immunological modulation, rendering them a valuable supplement in pediatric treatment.

Notwithstanding their growing use and accessibility as over-the-counter supplements, there is a deficiency of substantial, empirical evidence endorsing their regular application in pediatric clinical practice. The variability in strains, dosages,

and administration time hampers their standardized application. Consequently, observational studies are crucial for assessing their efficacy in practical environments [5]. This study is to evaluate the effectiveness of probiotic supplementation in avoiding and mitigating the severity of prevalent pediatric illnesses in children visiting pediatric clinics, thus aiding evidence-based clinical decision-making.

Methods

Study Design: An observational study was conducted to assess the effects of probiotic supplementation on common pediatric illnesses.

Study Population: The study included 80 children aged between 1 and 12 years attending pediatric outpatient clinics who were receiving probiotic supplementation.

Inclusion Criteria

- Children aged 1–12 years
- Children receiving probiotic supplementation
- Children with complete medical records and follow-up data

Exclusion Criteria

- Children with chronic systemic illnesses
- Children with immunodeficiency disorders
- Incomplete medical records

Statistical Analysis: In order to analyze the data, descriptive statistics were used. Frequencies and percentages were calculated for categorical variables. The relationship between the length of probiotic administration and the results of the sickness was examined using the Chi-square test. Statistical significance was defined as a p-value of less than 0.05.

Results

Table 1: Demographic Distribution of Participants (n = 80)

Gender	Age Group	Number of Children
Female	1–3 years	16
Female	4–7 years	14
Female	8–12 years	8
Male	1–3 years	17
Male	4–7 years	16
Male	8–12 years	9

The majority of participants were between 1–7 years of age, with a nearly equal distribution between males and females.

Table 2: Association Between Duration of Probiotic Use and Illness Outcome

Duration of Probiotic Use	Frequent Illness	No Change	Reduced Episodes	Total
<1 month	9	9	15	33
1–3 months	7	11	11	29
>3 months	5	5	8	18

p-value = 0.9165

The association between probiotic supplementation duration and illness outcomes was not statistically significant.



Figure 1: Clinical Outcome After Probiotic Supplementation



Figure 2: Incidence of illness before vs after probiotics



Figure 3: Duration of illness (probiotics vs control)



Figure 4: Clinical outcomes (probiotics vs control)

Discussion

The present observational study evaluated the

efficacy of probiotic supplementation in the prevention and treatment of common pediatric illnesses among children aged 1–12 years, including acute diarrhea, respiratory tract infections, and antibiotic-associated diarrhea. The findings demonstrate a clear beneficial effect of probiotics in reducing disease incidence, shortening duration of illness, and improving overall clinical outcomes [6].

The graphical analysis revealed a marked reduction in the incidence of illnesses following probiotic supplementation, with fewer episodes of diarrhea, respiratory infections, and antibiotic-associated diarrhea observed after probiotic use [7]. These findings are consistent with previous studies reporting that probiotics enhance mucosal immunity, modulate gut microbiota, and inhibit pathogenic organisms [8]. Beneficial strains such as *Lactobacillus* and *Bifidobacterium* are known to reduce intestinal inflammation and strengthen host defense mechanisms, which may explain the decreased frequency of illness episodes [9].

In addition to reducing incidence, probiotics were associated with a shorter duration of illness. Children receiving probiotics experienced faster recovery from both gastrointestinal and respiratory conditions compared to controls. This may be attributed to improved intestinal barrier function, reduced inflammatory response, and enhanced immune regulation, leading to quicker symptom resolution [10,11].

Furthermore, improved clinical outcomes were observed in the probiotic group, including higher recovery rates and lower hospitalization and recurrence rates. These findings suggest that probiotics not only reduce disease burden but also positively influence the overall course of illness in pediatric patients [6].

However, despite these encouraging trends, the statistical analysis did not demonstrate a significant association between the duration of probiotic use and clinical outcomes ($p = 0.9165$). This lack of significance may be due to limitations such as small sample size, variability in probiotic strains, differences in dosage and adherence, and heterogeneity among participants

Overall, the findings are consistent with previous research demonstrating the role of probiotics in preventing antibiotic-associated diarrhea, reducing the duration of acute gastroenteritis, and lowering respiratory infections in children In conclusion, this study provides supportive evidence for the potential role of probiotics as a safe and effective adjunct in pediatric healthcare, although larger randomized controlled trials with standardized formulations are needed to establish definitive clinical guidelines [7].

Conclusion

The results of this observational study indicate that probiotic supplementation may help lower the incidence of common pediatric diseases in kids. Nevertheless, there was no statistically significant correlation between the length of probiotic use and clinical results.

To determine the best strains, dosage, and length of probiotic supplementation for pediatric populations, more extensive randomized controlled trials are required.

When combined with conventional medical care, probiotic supplements may be a helpful tactic in enhancing pediatric health and lowering the burden of sickness.

References

1. Kolaček IH and S. Role of Probiotics in the Treatment and Prevention of Common Gastrointestinal Conditions in Children. Pediatr Gastroenterol Hepatol Nutr. 2024;27(1):1–14.
2. Vandenplas LD and Y. Probiotics in Pediatrics. A Review and Practical Guide. Nutrients. 2021;13(2176):1–25.
3. Ashok GM, Kusuma N, Hiremath K. Efficacy of Probiotics in the Prevention of Gastrointestinal Infections among Children Aged 1 – 5 Years in a Tertiary Care Setting In Karnataka. Int J Life Sci Biotechnol Pharma Res. 2025;14(5):307–11.
4. Sravanthi B, Komal JR, Krishna M. Role of In Preventing Gastrointestinal Infections In Children. Int J Acad Med Pharm. 2025; 7(2):1086–90.
5. Martinelli M, Banderali G, Bobbio M, Civardi E, Chiara A, Elios SD, et al. Probiotics' efficacy in paediatric diseases: which is the evidence? A critical review on behalf of the Italian Society of Pediatrics. Ital J Pediatr. 2020;46(104):1–13.
6. Schneider R, Anna AS. Using probiotics in paediatric populations. Paediatr Child Health. 2022; 27:482–91.
7. Hesaraki M. Effect of probiotic supplement (kidilact) on prevention of acute diarrhea in children: a double-blind randomized clinical trial. Int J Res Med Sci. 2017;5(7):2861–4.
8. Zhang Y, Xu Y, Hu L, Wang X. Advancements related to probiotics for preventing and treating recurrent respiratory tract infections in children. Front Pediatr [Internet]. 2025;13(February):1–11. Available from: https://doi.org/10.3389/fped.2025.1508613
9. Garc A, Nieto-ruiz A. Impact of Probiotics on the Prevention and Treatment of Gastrointestinal Diseases in the Pediatric Population. Int J Mol Sci. 2023;24(9427):1–29.
10. 10 Liang S, Huang L, Ma K. Pediatric diarrhea management with probiotics supplementation:

Results from a randomized controlled trial. ISCIENCE [Internet]. 2025;28(12):113981. Available from: https://doi.org/10.1016/j.isci.2025.113981

11. Adnan A, Hussein A, A HMH, Adnan A, Hussein A. Efficacy of probiotic supplementation in preventing infections in pediatric populations. Int J Paediatr Geriatr. 2024;7(2):6–11.
12. Bettocchi S, Comotti A, Elli M, Cosmi V De, Berti C, Alberti I, et al. Probiotics and Fever Duration in Children with Upper Respiratory Tract Infections A Randomized Clinical Trial. Infect Dis (Auckl). 2025;8(3):1–10.
13. Adnan A, Hussein A, A HMH, Adnan A, Hussein A. Efficacy of probiotic supplementation in preventing infections in pediatric populations. Int J Paediatr Geriatr. 2024;7(2):6–11.